The partnership marks Cardio Diagnostics' first expansion outside the US and is focused on integrating the test within Dr. Lal PathLabs' laboratory and clinical network.
Aranscia will provide software solutions to facilitate the delivery of results from InterVenn's flagship glycoproteomic liquid biopsy test.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback